The story of Dr. Reshma Kewalramani is more than a professional success – she is a symbol of transformation in global business and science. The prestigious recognition from Fortune, which ranks her among the hundred most influential world leaders for 2025, marks a turning point not only for her but for the entire industry.
The path of this exceptional researcher begins with immigration from Mumbai to the United States at just 11 years old. Her academic biography is marked by exceptional achievements – graduating with honors from Boston University and her subsequent doctoral degree, which make her one of the most significant experts in medical research.
Since 2020, Kewalramani has held the key position of CEO and President of the biopharmaceutical giant Vertex Pharmaceuticals. Under her leadership, the company has achieved remarkable scientific breakthroughs, introducing the first gene-editing therapies for severe hereditary diseases such as sickle cell anemia and beta-thalassemia.
One of her most significant contributions is the development of a revolutionary non-opioid pain medication that changes the understanding of pain treatment. The result of her expertise is impressive – Vertex's market value in 2025 exceeds 110 billion dollars.
Kewalramani's selection is seen as a strategic signal for a new era in technology and business. She consistently advocates for accessible medicine, investments in innovation, and equal opportunities for women and minority community representatives.
For Bulgaria, this example has a deep symbolic meaning. It demonstrates that scientific breakthroughs can truly transform the lives of millions of people. Interest in medical and technological careers is growing, and Bulgarian scientists are increasingly participating in global research projects.
The story of Dr. Reshma Kewalramani is more than an individual success – it is an inspiration for all who believe in the power of education, perseverance, and dreams.